However, these gain-of-functions effects were almost completely depleted by EREG-specific shRNAs (Supplementary Fig. 5a), which retained normal proliferative potential of stromal cells but reversed the malignant phenotypes of recipient cancer cells (Supplementary Fig. 5b–d). Here, EREG is linked to cancer.